SCHEMBL20533591

SCHEMBL20533591

CCOC(=O)N1CCN(c2cc(N)n3nc(C)c(-c4ccc5c(c4)c(C)nn5C)c3n2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.41
ALOX15 P16050 1/20 0.40
LMNA P02545 5/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
MAPT P10636 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
USP2 O75604 1/20 0.40
TP53 P04637 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
NPSR1 Q6W5P4 2/20 0.38
POLB P06746 1/20 0.37
ADRB2 P07550 1/20 0.37
ATM Q13315 1/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
RAD52 P43351 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20534141 0.84 PI4KB (0.47) DPP4LMNAMEN1KMT2AMAPT
SCHEMBL20533765 0.84 MAPT (0.51) LMNAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL20533568 0.80 MAPT (0.41) DPP4ALOX15LMNAMEN1KMT2A
SCHEMBL20533670 0.80 PI4KB (0.52) DPP4LMNAMEN1KMT2AMAPT
SCHEMBL20533660 0.77 PI4KB (0.35) DPP4LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL20533594 0.74 ALDH1A1 (0.36) LMNAMAPTSMN1; SMN2USP2NPSR1
SCHEMBL20533764 0.74 SMPD3 (0.34) DPP4LMNAMEN1KMT2AMAPT
SCHEMBL20533888 0.73 ABCG2 (0.35) DPP4LMNAMEN1KMT2AMAPT
SCHEMBL20533889 0.72 PI4KB (0.48) MAPTSMN1; SMN2USP2NPSR1HPGD
SCHEMBL20533573 0.71 MEN1 (0.49) LMNAMEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors PI4KA, PI4K2B, PI4KB DPP4 463/4885ALOX15 2648/4885LMNA 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.